Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Tetra Bio-Pharma Inc. (TBPMF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.0274-0.0001 (-0.22%)
At close: 03:09PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.0275
Open0.0274
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.0254 - 0.0290
52 Week Range0.0216 - 0.2267
Volume163,900
Avg. Volume88,271
Market Cap10.835M
Beta (5Y Monthly)1.91
PE Ratio (TTM)N/A
EPS (TTM)-0.0840
Earnings DateJul 14, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A

Subscribe to Yahoo Finance Plus to view Fair Value for TBPMF

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • TETRA BIO PHARMA INC
    Daily Spotlight: Alternative Investments Weak as WellAlternative investments are supposed to hedge against stock and bond market weakness. At least that's what the textbooks say. The most popular alternatives include Gold, Real Estate, Commodities, and, recently, Bitcoin. Only one of the alternatives (Commodities) has provided a respite for investors in 2022, with returns of 7% on the commodity benchmark ETF DBC. Gold isn't bad, down 5%. Real Estate held up early in the year -- but as interest rates have risen, the benchmark ETF IYR has fallen sharply and is down 21% YTD. Each of these is better than Crypto, of course. The approximately $1.0 trillion Cryptocurrency market has tumbled in recent months from $3.7 trillion amid a high level of volatility and a risk-off move in financial markets. Year-to-date, Bitcoin is down about 50%. In theory, consumers, investors, and traders are all attracted to Bitcoin. Given high inflation, we think Commodities will remain in demand and are the best-positioned alternative. In our view, Commodities should constitute up to 3%-5% of portfolios, with Copper and Paper/Corrugated Packaging having the most exposure due to positive long-term secular trends behind e-vehicles and e-commerce. We still think it is early to be adding volatile Bitcoin-related securities to our model portfolios at this time. We will reconsider Cryptocurrencies once the sector approaches total market capitalization of $5 trillion, or the regulatory outlook becomes clearer.
    Rating
    Fair Value
    Economic Moat
    5 days agoArgus Research
View more
  • CNW Group

    Tetra Bio-Pharma Inc. Announces Revised Terms and First Closing of Financing with Alpha Blue Ocean

    Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX: TBP) (OTCQB: TBPMF) (FRA: JAM1), a leader in cannabinoid-based drug discovery and development, announced today that the Company has revised the terms of its previously announced financing arrangement (the "Financing") with Global Corporate Finance Opportunities 16 (the "Investor"), an investment vehicle advised by Alpha Blue Ocean ("ABO"), and has closed the first tranche of the Financing on such revised terms, the whole pursuant to the term

  • CNW Group

    IIROC Trade Resumption - TBP

    Trading resumes in:

  • PR Newswire

    Tetra Collaborates with Cellvera to Develop a Potential Oral Combination Treatment for COVID-19 Patients

    Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX: TBP) (OTCQB: TBPMF) (FRA: JAM1), a leader in cannabinoid-derived drug discovery and development announced today they signed an agreement with Cellvera Global Holdings LLC ("Cellvera"), for the co-development of ARDS-003 as a combination product, with Qifenda 400MG (Favipiravir), a commercial-stage broad-spectrum antiviral drug.

Advertisement
Advertisement